BD Completes Acquisition of TriPath Imaging
December 20 2006 - 8:51AM
PR Newswire (US)
Expands Presence in Cancer Diagnostics Market FRANKLIN LAKES, N.J.,
Dec. 20 /PRNewswire-FirstCall/ -- BD (Becton, Dickinson and
Company) (NYSE:BDX) today announced the completion of its
acquisition of TriPath Imaging (NASDAQ:TPTH), a maker of innovative
solutions to improve the clinical management of cancer. The
acquisition was finalized in accordance with terms originally
disclosed in an announcement issued by BD on September 8, 2006.
This strategic acquisition aligns innovative new technologies with
BD's existing business strategies and is a natural complement to
ongoing internal research programs in its BD Diagnostics and BD
Biosciences segments. These oncology management tools are intended
to span cancer screening, diagnosis, prognosis and therapy
monitoring, especially for cancers affecting women's health,
including breast, cervical and ovarian. This transaction also
further demonstrates BD's commitment to bringing new technologies
and innovation to difficult problems in healthcare, which is in
line with the Company's purpose of "Helping all people live healthy
lives." About BD BD, a leading global medical technology company
that manufactures and sells medical devices, instrument systems and
reagents, is dedicated to improving people's health throughout the
world. BD is focused on improving drug therapy, enhancing the
quality and speed of diagnosing infectious diseases, and advancing
research and discovery of new drugs and vaccines. The Company's
capabilities are instrumental in combating many of the world's most
pressing diseases. Founded in 1897 and headquartered in Franklin
Lakes, New Jersey, BD employs more than 25,000 people in
approximately 50 countries throughout the world. The Company serves
healthcare institutions, life science researchers, clinical
laboratories, industry and the general public. For more
information, please visit http://www.bd.com/. This press release
contains certain estimates and other forward-looking statements (as
defined under Federal securities laws) regarding BD's performance,
including future performance, products or other events or
developments that BD expects to occur or anticipates occurring in
the future. All such statements are based upon current expectations
of BD and involve a number of business risks and uncertainties.
Actual results could vary materially from anticipated results
described, implied or projected in any forward-looking statement.
Factors that could cause actual results to vary materially from any
forward-looking statement include, but are not limited to:
competitive factors; pricing and market share pressures;
difficulties inherent in product development and delays in product
introductions; changes in regional, national or foreign economic
conditions; increases in energy costs and their effect on, among
other things, the cost of producing BD's products; fluctuations in
costs and availability of raw materials and in BD's ability to
maintain favorable supplier arrangements and relationships; changes
in healthcare or other governmental regulation; as well as other
factors discussed in this press release and in BD's filings with
the Securities and Exchange Commission. We do not intend to update
any forward-looking statements to reflect events or circumstances
after the date hereof except as required by applicable laws or
regulations. DATASOURCE: BD (Becton, Dickinson and Company)
CONTACT: Colleen T. White, Corporate Communications,
+1-201-847-5369, or Patricia A. Spinella, Investor Relations,
+1-201-847-5453 Web site: http://www.bd.com/
Copyright
Tripath Imaging (NASDAQ:TPTH)
Historical Stock Chart
From Apr 2024 to May 2024
Tripath Imaging (NASDAQ:TPTH)
Historical Stock Chart
From May 2023 to May 2024